2,117 research outputs found

    Industrial sprawl and residential housing. Exploring the interplay between local development and land-use change in the Valencian Community, Spain

    Get PDF
    Urbanization in Mediterranean Europe has occurred in recent decades with expansion of residential, commercial and industrial settlements into rural landscapes outside the traditional metropolitan boundaries. Industrial expansion in peri-urban contexts was particularly intense in Southern Europe. Based on these premises, this work investigates residential and industrial settlement dynamics in the Valencian Community, Spain, between 2005 and 2015, with the aim to clarify the role of industrial expansion in total urban growth in a paradigmatic Mediterranean region. Since the early 1990s, the Valencian industrial sector developed in correspondence with already established industrial nodes, altering the surrounding rural landscape. Six variables (urban hierarchy, discontinuous settlements, pristine land under urban expansion, isolated industrial settlements, within- and out-of-plan industrial areas) were considered with the aim at exploring land-use change. Empirical results indicate a role of industrial development in pushing urban sprawl in coastal Valencia. A reflection on the distinctive evolution of residential and industrial settlements is essential for designing new planning measures for sustainable land management and containment of urban sprawl in Southern Europe. A comparative analysis of different alternatives of urban development based on quantitative assessment of land-use change provides guidelines for local development and ecological sustainability

    Pancreatic cancer-associated diabetes mellitus: an open field for proteomic applications.

    Get PDF
    Background: Diabetes mellitus is associated with pancreatic cancer in more than 80% of the cases. Clinical, epidemiological, and experimental data indicate that pancreatic cancer causes diabetes mellitus by releasing soluble mediators which interfere with both beta-cell function and liver and muscle glucose metabolism. Methods: We analysed, by matrix-assisted laser desorption ionization time of flight (MALDI-TOF), a series of pancreatic cancer cell lines conditioned media, pancreatic cancer patients' peripheral and portal sera, comparing them with controls and chronic pancreatitis patients' sera. Results: MALDI-TOF analysis of pancreatic cancer cells conditioned media and patients' sera indicated a low molecular weight peptide to be the putative pancreatic cancer-associated diabetogenic factor. The sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis of tumor samples from diabetic and non-diabetic patients revealed the presence of a 1500 Da peptide only in diabetic patients. The amino acid sequence of this peptide corresponded to the N-terminal of an S-100 calcium binding protein, which was therefore suggested to be the pancreatic cancer-associated diabetogenic factor. Conclusions: We identified a tumor-derived peptide of 14 amino acids sharing a 100% homology with an S-100 calcium binding protein, which is probably the pancreatic cancer-associated diabetogenic facto

    Pancreatic cancer-derived S-100A8 N-terminal peptide: a diabetes cause?

    Get PDF
    BACKGROUND: Our aim was to identify the pancreatic cancer diabetogenic peptide. METHODS: Pancreatic tumor samples from patients with (n=15) or without (n=7) diabetes were compared with 6 non-neoplastic pancreas samples using SDS-PAGE. RESULTS: A band measuring approximately 1500 Da was detected in tumors from diabetics, but not in neoplastic samples from non-diabetics or samples from non-neoplastic subjects. Sequence analysis revealed a 14 amino acid peptide (1589.88 Da), corresponding to the N-terminal of the S100A8. At 50 nmol/L and 2 mmol/L, this peptide significantly reduced glucose consumption and lactate production by cultured C(2)C(12) myoblasts. The 14 amino acid peptide caused a lack of myotubular differentiation, the presence of polynucleated cells and caspase-3 activation. CONCLUSIONS: The 14 amino acid peptide from S100A8 impairs the catabolism of glucose by myoblasts in vitro and may cause hyperglycemia in vivo. Its identification in biological fluids might be helpful in diagnosing pancreatic cancer in patients with recent onset diabetes mellitus

    La hipoglucemia incrementa el gasto en salud y deteriora la productividad de pacientes con diabetes tipo 1 y tipo 2

    Get PDF
    La hipoglucemia es la dificultad más temida del tratamiento con insulina, con posible impacto social y sobre la utilización de recursos en salud, aspectos evaluados infrecuentemente. Objectivos: Describir el impacto de la hipoglucemia sobre el desempeño social y el uso de recursos en salud, en pacientes argentinos del estudio HAT. Metodologías: Estudio internacional, no intervencional que evaluó hipoglucemia severa (HS) y no severa (HNS) en pacientes con DM1 y DM2 tratados con insulina, mediante cuestionarios de autoreporte: el 1° transversal retrospectivo sobre periodos de 6 meses (HS) y 4 semanas (HNS) y el 2° prospectivo de 28 días (HS e HNS). Resultados: Participaron 1253 pacientes (DM1: 433, DM2: 823); en promedio, edad 41.7 y 63 años, duración de la diabetes 17.6 y 15.4 años y HbA1c 8.1% y 7.8% para DM1 y DM2 respectivamente. En el período retrospectivo 82.7% (DM1) y 48.6% (DM2) informaron al menos 1 HNS; 37.9% y 16.3% comunicaron HS. En el período prospectivo, 88.1% y 44.6% reportaron HNS, 21.5% y 8.5% HS para DM1 y DM2 respectivamente. En el período retrospectivo, 24(6.1%) pacientes y 16(3.2%) requirieron admisión hospitalaria, 13(3.4%) y 23(5%) asistieron a consultas adicionales y 75(19.6%) y 84(18.2%) se comunicaron telefónicamente con algún integrante del sistema de salud, debido a una hipoglucemia para DM1 y DM2, respectivamente. Desempeño laboral (período retrospectivo) los pacientes faltaron 3.1(3) y 5.8(7.9), llegaron tarde 3.5(3.9) y 6.9(9.4), se retiraron antes 10.5(53.5) y 4.7(8.4) (días en promedio [DS]) para DM1 y DM2 respectivamente. En el período prospectivo faltaron 2.5(3) y 2.7(1.2), llegaron tarde 1.4(0.9) y 1.3(0.5), se retiraron antes 1.7(1) y 1.3(0.5) días para DM1/DM2 respectivamente. Conclusiones: En una muestra de personas de la Argentina con DM1 y DM2 tratados con insulina, la hipoglucemia generó mayor uso de recursos en salud y deterioró el desempeño laboral/académico de los pacientes.Facultad de Ciencias Médica

    A novel homozygous variant extending the peripheral myelin protein 22 by 9 AMino acids causes early-onset Charcot-Marie-Tooth disease with predominant severe sensory ataxia

    Get PDF
    Peripheral myelin protein 22 (PMP22) related neuropathies account for over 50% of inherited peripheral neuropathies. A gene copy variation results in CMT1A (duplication) and hereditary neuropathy with liability to pressure palsies (HNPP; single deletion). Point mutations comprise both phenotypes. The underlying pathological mechanisms are incompletely understood and biallelic mutations of PMP22 are very rare. We describe a 9‐year‐old girl who presented before the age of 1 year with severe locomotor delay. She now requires support for standing and walking in view of her severe sensory ataxia. Strikingly, her muscle power and bulk are close to normal in all segments. Nerve conduction studies showed sensory‐motor velocities below 5 m/s. Genetic analysis revealed a homozygous sequence change in the PMP22 gene causing the loss of termination codon (c.483A > G; p.[*161Trpext*10]), extending the protein by 9 amino acids. Both heterozygous parents have neurophysiological abnormalities consistent with HNPP, consistent with this being a loss‐of‐function mutation. PMP22‐deficient human models are rare but important to decipher the physiological function of the PMP22 protein in vivo. The predominance of large fiber sensory involvement in this and other rare similar cases suggests a pivotal role played by PMP22 in the embryogenesis of dorsal root ganglia in humans

    Discharge quality from municipal wastewater treatment plants and the Sludge Biotic Index for activated sludge: integrative assessment

    Get PDF
    Abstract Wastewater treatment plants (WWTPs) are scrutinized by Environmental Authorities particularly regarding the compliance to discharge limit values fixed by national and local regulations. An integrated approach is necessary to achieve the objectives established with Directive 2000/60/EC (WFD) considering the ecological status of the receiving water body and the quality of the discharge. Specifically, documentary, technical, management and analytical controls should be developed. Moreover, integrative information on the behaviour of the activated sludge in the aeration tank can be useful for plant managers as well as for the regulating Authorities. The study presents the experience concerning WWTP regulation considering the analytic assessment of the discharge as well the monitoring of the Sludge Biotic Index (SBI) for activated sludge. Data from monitoring during the period 2008–14 on SBI values and chemical and microbiological data on the discharges of a sample of 35 WWTPs in the province of Venice (north-east Italy, Veneto region) are presented and discussed. Together with chemical and microbiological analysis, the SBI appears to be a highly useful index for the integrative assessment of plant functionality, in particular when monitoring and identifying critical situations that can determine the exceedance of discharge limit values. The SBI method, in an integrated control approach, can be used for small and medium sized WWTPs that only treat domestic wastewaters. In a case by case assessment this may even substitute part of the analytical monitoring carried out in the WWTPs' control process
    corecore